In patients with chronic rheumatic diseases, misleading symptoms can delay cancer diagnosis. In this study, researchers evaluated whether a metabolic signature could indicate paraneoplasia or reveal concomitant cancer in patients with rheumatic musculoskeletal disease. Metabolic markers were quantified in the sera of 56 patients with rheumatoid arthritis or ankylosing spondylitis and 52 patients without known rheumatic disease. A diagnostic cancer model was developed using levels of acetate, creatine, glycine, formate and the L1/L6 lipid ratio.
Last press reviews
COVID-19 and coagulation parameters: a link to mortality?
The COVID-19 pandemic, caused by SARS-CoV-2, has led to millions of deaths...
Resistance training and Multiple Sclerosis: a solution to improve function and quality of life?
Multiple sclerosis (MS) is a chronic autoimmune disease of the central ner...
Endometriosis: the Impact of hormones, sexual practice, and surgical treatments
Endometriosis is a chronic inflammatory disease modulated by estrogen leve...